April 14, 2026 | Read online

Midweek Setup: Why (MDCX) Is Lining Up for Tomorrow’s Watchlist

Any content you receive is for information purposes only. Always conduct your own research.

*Disseminated on Behalf of Medicus Pharma Ltd.

Market Maven Insights Puts Medicus Pharma Ltd. (NASDAQ: MDCX) on Its Watchlist For Tomorrow Morning—Wednesday, April 15, 2026.

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

You Can Expect Our Full Coverage On (MDCX) To Start Early

Take A Look At (MDCX) Before Tomorrow Morning

April 14, 2026

Midweek Setup | Why (MDCX) Is Lining Up for Tomorrow’s Watchlist

Dear Reader,

In healthcare, meaningful change often doesn’t arrive all at once, it starts by challenging long-standing standards that few have questioned.

For basal cell carcinoma, that standard has traditionally centered around surgical removal.

While effective, it isn’t without trade-offs, especially for patients dealing with multiple or recurring lesions over time.

Now, a different approach is beginning to emerge, one focused on localized delivery, designed to target affected tissue more directly.

Early clinical data is starting to reflect that shift.

In a recent Phase 2 study, this method demonstrated clinical clearance in a notable portion of patients at higher dose levels.

Market Maven Insights focuses on these early-stage shifts before they become widely recognized, and one company currently exploring this approach is Medicus Pharma Ltd. (NASDAQ: MDCX).

That’s a key reason (MDCX) has moved to the top of our watchlist heading into tomorrow morning—Wednesday, April 15, 2026.

There’s also an additional layer worth noting.

Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, has issued a $6 target on (MDCX) implying approximately 1,400% upside potential from its recent $0.40 range.

Based in Philadelphia, Medicus Pharma operates with a capital-efficient strategy aimed at advancing high-potential therapeutic assets without the burden of full-scale commercialization.

Rather than carrying programs through late-stage global rollout, the company’s model focuses on progressing candidates through Phase 2 proof-of-concept, then pursuing licensing agreements or strategic partnerships with larger pharmaceutical players.

This approach is currently centered around two core platforms: SkinJect™ for dermatology and oncology applications, and the Teverelix hormone-suppression program.

Dermatology Platform: SkinJect™ and the D-MNA Approach

At the center of (MDCX)’s dermatology strategy is SkinJect™ (D-MNA)—a localized immuno-oncology product built around precision delivery.
The platform uses a patented dissolvable microneedle patch designed to administer doxorubicin directly into basal cell carcinoma (BCC) lesions.

Rather than relying on traditional surgical removal, this approach focuses on targeted, non-invasive delivery, an option that may be particularly relevant for patients managing multiple or recurring lesions where procedures can become more complex.

Here’s what’s been developing:

Phase 2 Progress: In December 2025, (MDCX) completed enrollment of 90 patients in its U.S.-based, randomized, double-blind Phase 2 study (SKNJCT-003).

Topline Data: Early 2026 results pointed to strong signals, with the highest dose group (200ug) showing clinical clearance rates of up to 73%.

Potential Impact: Based on these findings, key opinion leaders have indicated that roughly 3 out of 4 patients treated at the optimal dose level may be able to avoid immediate surgical intervention.

Regulatory Strategy: Following a Type C meeting with the FDA, the company is now exploring a 505(b)(2) regulatory pathway, a route that could help streamline development timelines compared to traditional approval processes.

Hormone-Suppression Platform: Teverelix

In August 2025, (MDCX) broadened its pipeline with the acquisition of Antev, a UK-based biotech advancing Teverelix, a next-generation, long-acting GnRH antagonist.

The program is designed to suppress sex hormone production while avoiding the initial “testosterone flare” commonly seen with older GnRH agonists, an effect that can create complications during early treatment.

Here’s what stands out:

Targeted Mechanism: Teverelix’s approach may offer a more controlled hormone suppression profile, which could be particularly relevant for patients with advanced prostate cancer.

Cardiovascular Considerations: By avoiding hormonal surges, the therapy may help reduce added physiological stress, an important factor for patients with elevated cardiovascular risk.

Regulatory Progress: In February 2026, the FDA provided “study may proceed” clearance for a Phase 2b dose-optimization trial in men with advanced prostate cancer.

Improved Economics: (MDCX) has also refined the program’s long-term structure, reducing the royalty obligation on worldwide net sales from approximately 4% to 2%, potentially strengthening future margins.

AI-Driven Development Strategy: Advancing Through Simulation

One of the more distinctive elements of (MDCX)’s approach is its integration of agentic AI to enhance how clinical programs are designed and executed.

In December 2025, (MDCX) announced a collaboration with Reliant AI Inc., focused on building a platform aimed at improving efficiency across key stages of development.

Here’s how that strategy is taking shape:

Protocol Modeling: Trial designs can be tested in simulated environments before real-world enrollment begins—helping refine structure and reduce potential inefficiencies early.

Smarter Site Selection: The platform is designed to identify locations with higher concentrations of target patient populations, which may support faster and more effective enrollment.

Data-Guided Patient Selection: By leveraging pharmacodynamic insights, the system aims to prioritize participants most likely to respond, potentially improving trial clarity and reducing overall development risk.

Financial Snapshot and Positioning

As of the second quarter of 2026, (MDCX) carries an approximate market capitalization of $16M, with a reported cash position of $8.7M.

Over the course of fiscal year 2025, the company secured roughly $31.9M in total financing, capital that has been directed toward advancing its Phase 2 clinical programs at an accelerated pace.

Like many development-stage biotech companies, (MDCX) is currently operating at a net loss, reporting approximately $47.3M for FY2025. However, management continues to emphasize a capital-efficient strategy focused on generating near-term value through clinical proof-of-concept milestones, rather than committing to the significant costs associated with full-scale commercialization.

Recent Developments and Updates:

Phase 2 Data (SkinJect™): (MDCX) reported and further expanded on its Phase 2 SKNJCT-003 results, with up to 73% clinical clearance observed in the highest dose group. The full Clinical Study Report is expected in Q2 2026, supporting a planned End-of-Phase-2 FDA meeting.

Regulatory Progress (Teverelix): In February 2026, (MDCX) received FDA “study may proceed” clearance to initiate a Phase 2b dose-optimization trial in advanced prostate cancer.

Strategic Visibility: (MDCX) also increased its presence at major industry events, including the Longwood Miami CEO Forum and the Roth Conference, where leadership highlighted its AI-driven development strategy and pipeline progress.

Together, these updates point to a company entering a potential catalyst-driven phase, with ongoing clinical, regulatory, and strategic developments unfolding.

Why (MDCX) Is At The Top of Our Watchlist Tomorrow Morning
7 Key Factors — Wednesday, April 15, 2026

1. Clinical Data Gaining Attention: Recent Phase 2 results showed up to a 73% clinical clearance rate in higher dose cohorts, pointing to measurable biological activity.

2. Alternative Approach Emerging: (MDCX)’s localized microneedle delivery system is designed to target lesions directly, offering a different path compared to traditional surgical methods.

3. Expanded Pipeline Exposure:
With the addition of Teverelix, (MDCX) now has a second program focused on hormone suppression without the initial flare associated with older therapies.

4. Regulatory Progress in Motion: A recent “study may proceed” clearance enables the company to advance into a Phase 2b study in patients with advanced prostate cancer.

5. Focused Development Model: (MDCX) is structured to move assets through Phase 2 and pursue licensing or strategic partnerships, rather than building a full commercial footprint.

6. AI-Driven Trial Optimization: Through its collaboration with Reliant AI, the company is leveraging simulation and data-driven tools to refine trial design and patient selection.

7. Analyst Perspective: One biotech analyst has issued a $6 target on (MDCX), implying approximately 1,400% upside from its recent $0.40 range.

Pull Up (MDCX) Before Tomorrow Morning…

When you step back and look at the full picture, multiple pieces are beginning to align.

On the clinical side, SkinJect has already delivered Phase 2 data showing up to 73% clinical clearance in higher dose cohorts, early evidence of activity in a real-world setting.

At the same time, Teverelix adds a second program now moving forward following FDA clearance, focused on hormone suppression without the initial flare seen in legacy treatments.

Then there’s the structure behind it all.

(MDCX) is built to advance assets through mid-stage development and position them for potential licensing or strategic partnerships, rather than taking on the cost of full commercialization.

Layer in the company’s use of AI-driven simulation to refine trial design and execution, and the overall strategy starts to come into focus.

An analyst’s $6 target, implying roughly 1,400% upside potential from recent levels, adds another perspective worth considering within the broader setup.

We’ll be watching (MDCX) closely tomorrow morning.

Take a moment to get familiar with the story tonight, our next update could come early.

Sincerely,
Tate Remington
Chief Editor, Market Maven Insights

^{MarketMavenInsights.com}^{(“MarketMavenInsights” or “MMI”) is owned by Source Coastal Media LLC, a multi member limited liability company. Data is provided from third-party sources and MMI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MMI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.}

^{Pursuant to an agreement between Source Coastal Media LLC and TD Media LLC, Source Coastal Media LLC has been hired for a period beginning on 04/14/2026 and ending on 04/15/2026 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, TD Media LLC has paid Source Coastal Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Source Coastal Media LLC has been paid forty four thousand eight hundred USD (“Funds”). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

^{Neither Source Coastal Media LLC, TD Media LLC and their member own shares of (MDCX:US).}

^{Please see important disclosure information here:}^{https://marketmaveninsights.com/disclosure/mdcx-7E33I/#details}